Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer

Long noncoding RNAs (lncRNAs) have multiple functions in the cancer immunity response and the tumor microenvironment. To investigate the immune-related lncRNA (IRlncRNA) signature for predicting prognosis and immunotherapeutic response in bladder cancer (BLCA), we extracted BLCA data from The Cancer Genome Atlas (TCGA) database. Finally, a total of 405 cases were enrolled and 8 prognostic IRlncRNAs (MIR181A2HG, AC114730.3, LINC00892, PTPRD-AS1, LINC01013, MRPL23-AS1, LINC01395, AC002454.1) were identified in the training set. Risk scores were calculated to divide patients into high-risk and low-risk groups, and the high-risk patients tended to have a poor overall survival (OS). Multivariate Cox regression analysis confirmed that the IRlncRNA signature could be an independent prognostic factor. The results were subsequently confirmed in the validating set. Additionally, this 8-IRlncRNA classifier was related to recurrence free survival (RFS) of BLCA. Functional characterization revealed this signature mediated immune-related phenotype. This signature was also associated with immune cell infiltration (i.e., macrophages M0, M2, Tregs, CD8 T cells, and neutrophils) and immune checkpoint inhibitors (ICIs) immunotherapy-related biomarkers [mismatch repair (MMR) genes, tumor mutation burden (TMB) and immune checkpoint genes]. The present study highlighted the value of the 8-IRlncRNA signature as a predictor of prognosis and immunotherapeutic response in BLCA.

• Publication year

  2020

• Venue

  Aging

• Publication date

  2020-11-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/aging.104115PMID 33221763PMCID 7746369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.

  2020cited by this paper
• Long Noncoding RNA MRPL23-AS1 Promoteoid Cystic Carcinoma Lung Metastasis

  2020cited by this paper
• Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers

  2020cited by this paper
• Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma

  2020cited by this paper
• A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer

  2020cited by this paper
• Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer

  2020cited by this paper
• Prognostic value of long non-coding RNA signatures in bladder cancer

  2019cited by this paper
• Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer

  2019cited by this paper
• Development of a novel six‐long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma

  2019cited by this paper
• Management of metastatic bladder cancer.

  2019cited by this paper
• ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

  2019cited by this paper
• Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

  2019cited by this paper
• Cancer statistics, 2019

  2019cited by this paper
• The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

  2019cited by this paper
• Bladder cancer survival nomogram

  2019cited by this paper
• An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer

  2019cited by this paper
• NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death

  2018cited by this paper
• Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer

  2018cited by this paper
• Lnc-chop Promotes Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor and Inflammatory Environments

  2018cited by this paper
• Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• A urinary microRNA (miR) signature for diagnosis of bladder cancer.

  2018cited by this paper
• Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout

  2018cited by this paper
• Long noncoding RNAs as regulators of cancer immunity

  2018cited by this paper
• Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

  2018cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017influential reference
• An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme

  2017cited by this paper
• Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.

  2017cited by this paper
• Long Noncoding RNA and Cancer: A New Paradigm.

  2017cited by this paper
• The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma

  2017cited by this paper
• Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma

  2017cited by this paper
• Bladder cancer

  2016cited by this paper
• EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

  2016cited by this paper
• Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.

  2016cited by this paper
• The emerging role of lncRNAs in cancer

  2015cited by this paper
• Robust enumeration of cell subsets from tissue expression profiles

  2015cited by this paper
• Long noncoding RNA in prostate, bladder, and kidney cancer.

  2014cited by this paper
• [Management of metastatic bladder cancer].

  2014cited by this paper
• Epidemiology and risk factors of urothelial bladder cancer.

  2013cited by this paper
• Inferring tumour purity and stromal and immune cell admixture from expression data

  2013cited by this paper
• Posttranscriptional gene regulation by long noncoding RNA.

  2013cited by this paper
• Long Noncoding RNAs: Past, Present, and Future

  2013cited by this paper
• edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

  2009cited by this paper
• GSEA-P: a desktop application for Gene Set Enrichment Analysis

  2007cited by this paper
• Bladder cancer.

  1998cited by this paper
• Cancer statistics

  1989cited by this paper
• SUPPLEMENTARY NOTE

  1879cited by this paper

• Disrupting Immune Silence: Non-Coding RNAs Targeting the PD-1/PD-L1 Axis in Tumor Immunity

  2026cites this paper
• Mitochondrial ribosomal proteins: potential targets for cancer prognosis and therapy

  2025cites this paper
• LINC00892 as a Prognostic Biomarker in Lung Adenocarcinoma: Role in Immune Infiltration and EMT Suppression

  2025cites this paper
• Natural killer cell-related gene signature predicts immune cell infiltration and improved survival in bladder cancer.

  2025cites this paper
• Identification of endoplasmic reticulum stress-associated lncRNAs influencing inflammation and VSMC function in abdominal aortic aneurysm

  2025cites this paper
• Subtype cluster analysis unveiled the correlation between m6A- and cuproptosis-related lncRNAs and the prognosis, immune microenvironment, and treatment sensitivity of esophageal cancer

  2025cites this paper
• The MIR181A2HG/miR‐5680/VCAN‐CD44 Axis Regulates Gastric Cancer Lymph Node Metastasis by Promoting M2 Macrophage Polarization

  2025cites this paper
• Alteration of lncRNA RHPN1-AS1 predicts clinical prognosis and regulates the progression of bladder cancer via modulating miR-485-5p

  2024cites this paper
• Novel Therapeutic Targets and Biomarkers Associated with Bladder Cancer‐Associated Fibroblasts (CAFs) Promoted by Bisphenol A

  2024cites this paper
• Cuproptosis-Related lncRNA Predict Prognosis and Immune Response of LUAD

  2024cites this paper
• Long Noncoding RNA Expression in Acute Lymphoblastic Leukemia: A Systematic Review.

  2024cites this paper
• Molecular map of cGAS-STING pathway-related genes in bladder cancer: the perspective toward immune microenvironment and prognosis

  2024cites this paper
• Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer

  2024cites this paper
• High Expression of MRPL23 Is Associated with Poor Survival in Clear-Cell Renal Cell Carcinoma

  2024cites this paper
• Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis

  2024cites this paper
• Identifying functional cuproptosis-related long non-coding RNAs in patients with bladder cancer

  2024cites this paper
• Integration analysis of cis- and trans-regulatory long non-coding RNAs associated with immune-related pathways in non-small cell lung cancer

  2024cites this paper
• Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer

  2024cites this paper
• Construction of Immune Infiltration-Related LncRNA Signatures Based on Machine Learning for the Prognosis in Colon Cancer

  2023cites this paper
• Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer

  2023cites this paper
• Construction and validation of a bladder cancer risk model based on autophagy-related genes

  2023cites this paper
• Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer

  2023cites this paper
• Identification of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer

  2023cites this paper
• Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model

  2023cites this paper
• Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer

  2023cites this paper
• Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer

  2023cites this paper
• Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer

  2023cites this paper
• The mitochondrial energy metabolism pathway-related signature predicts prognosis and indicates immune microenvironment infiltration in osteosarcoma

  2023cites this paper
• Identification and experimental validation of mitochondria-related genes biomarkers associated with immune infiltration for sepsis

  2023cites this paper
• Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

  2023cites this paper
• Epigenetic and Immunological Features of Bladder Cancer

  2023cites this paper
• 基于离子通道相关基因的膀胱癌患者预后风险评估模型构建

  2023cites this paper
• Identification of an immune gene-associated prognostic signature in patients with bladder cancer

  2022cites this paper
• A novel prognostic signature for lung adenocarcinoma based on cuproptosis-related lncRNAs: A Review

  2022cites this paper
• Based on Bioinformatics Studies on the Effect of a lpha1H on Key Genes, Pathways in Bladder Cancer and lncRNA on Patient Prognosis

  2022cites this paper
• Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients

  2022cites this paper
• Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer

  2022cites this paper
• Identification and Validation of an EMT-Related LncRNA Signature for HNSCC to Predict Survival and Immune Landscapes

  2022cites this paper
• Long Noncoding RNA Mediated Regulation in Human Embryogenesis, Pluripotency, and Reproduction

  2022cites this paper
• LncRNA GACAT3: A Promising Biomarker and Therapeutic Target in Human Cancers

  2022cites this paper
• A Novel Risk Model Identified Based on Pyroptosis-Related lncRNA Predicts Overall Survival and Associates With the Immune Landscape of GC Patients

  2022cites this paper
• Identification of an immune gene-associated prognostic signature in patients with bladder cancer

  2022cites this paper
• A Prognostic Model of Bladder Cancer Based on Metabolism-Related Long Non-Coding RNAs

  2022cites this paper
• Identification of a novel immune-related long noncoding RNA signature to predict the prognosis of bladder cancer

  2022cites this paper
• The Involvement of Long Non-coding RNA and Messenger RNA Based Molecular Networks and Pathways in the Subacute Phase of Traumatic Brain Injury in Adult Mice

  2022cites this paper
• E-cadherin expressions on bladder and its association with cancer progressivity: a retrospective cohort study

  2022cites this paper
• Constructing an immune‐ and ferroptosis‐related lncRNA signature to predict the immune landscape of human bladder cancer

  2022cites this paper
• Potential of Mitochondrial Ribosomal Genes as Cancer Biomarkers Demonstrated by Bioinformatics Results

  2022cites this paper
• Identification of a Genomic Instability-Related Long Noncoding RNA Prognostic Model in Colorectal Cancer Based on Bioinformatic Analysis

  2022cites this paper
• Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy

  2022cites this paper
• Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer

  2022cites this paper
• Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma

  2022cites this paper
• Identification of Nine M6A-Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas

  2022cites this paper
• Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer

  2022cites this paper
• Comprehensive analysis of the endoplasmic reticulum stress-related long non-coding RNA in bladder cancer

  2022cites this paper
• Computational identification of immune-related lncRNA signature for predicting the prognosis and immune landscape of human glioblastoma multiforme

  2022cites this paper
• An Immune-Related lncRNA Pairing Model for Predicting the Prognosis and Immune-Infiltrating Cell Condition in Human Ovarian Cancer

  2022cites this paper
• A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs

  2022cites this paper
• Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.

  2022cites this paper
• Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer

  2022cites this paper
• Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma

  2022cites this paper
• Epithelial-mesenchymal transition-related lncRNAs associated with prognosis and immune cell infiltration in lung adenocarcinoma.

  2022cites this paper
• Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation

  2022cites this paper
• Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer

  2022cites this paper
• Construction and validation of a novel algorithm based on oncosis-related lncRNAs comprising the immune landscape and prediction of colorectal cancer prognosis

  2022cites this paper
• Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers.

  2021cites this paper
• Identi cation of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer

  2021cites this paper
• Emerging Roles of Long Noncoding RNAs in Immuno-Oncology

  2021cites this paper
• Prognostic Value of a Pyroptosis-Related Long Noncoding RNA Signature Associated with Osteosarcoma Microenvironment

  2021cites this paper
• An immune-related lncRNA model for predicting prognosis, immune landscape and chemotherapeutic response in bladder cancer

  2021cites this paper
• Construction of immune-related lncRNA signature to predict aggressiveness, immune landscape, and drug resistance of colon cancer

  2021cites this paper
• Identification of immune infiltration-related LncRNA FAM83C-AS1 for predicting prognosis and immunotherapy response in colon cancer.

  2021cites this paper
• Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion

  2021cites this paper
• Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies.

  2021cites this paper
• LncRNA PSMA3‐AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR‐378a‐3p/GALNT3 axis

  2021cites this paper
• Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model

  2021cites this paper
• Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR‐616‐5p/DUSP2 axis

  2021cites this paper
• A Novel Signature Constructed by Immune-Related LncRNA Predicts the Immune Landscape of Colorectal Cancer

  2021cites this paper
• Prognostic value of immune-related lncRNA pairs in patients with bladder cancer

  2021cites this paper
• A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer

  2021cites this paper
• m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer

  2021cites this paper
• A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer

  2021cites this paper
• Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

  2021cites this paper
• Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer

  2021cites this paper
• Lnc13728 facilitates human mesenchymal stem cell adipogenic differentiation via positive regulation of ZBED3 and downregulation of the WNT/β-catenin pathway

  2021cites this paper